Financial News
Headline News about Y-Mabs Therapeutics Inc
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/earnings_image_1962.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/cells-gdd37bc5d2_1920_13.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/ep_us_feature_image_930.jpeg)
![](https://cdn.benzinga.com/files/images/story/2012/mid-afternoon-market-update_128.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/cells-1872666_1920_84.jpg)
Via Benzinga
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/earnings_scheduled_1856.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/biotech7.jpg)
![](https://cdn.benzinga.com/files/images/story/2012/mid-day-market-update_128.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_391.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/mid-day_movers_image_119.jpg)
![](https://cdn.benzinga.com/files/images/story/2012/mid-morning-market-update_127.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_811.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_1023.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_624.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_266.jpeg)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2021/analyst_ratings_image_2967.jpeg?width=720)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_324.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/cells-1872666_1920_102.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_56.png)
Y-mAbs Asked To Submit Additional Granularity Of Data For Omburtamab In Nerve Tissue Cancer
April 20, 2021
Via Benzinga
Exposures
Product Safety
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/biotech2_2.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_261.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/earnings_scheduled_1916.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/girl-with-red-hat-lm1kouw8kaa-unsplash.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_198.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_325.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.